{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:06:35Z","timestamp":1790388395382,"version":"4.1.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inclisiran is a novel small interfering RNA therapeutic developed to lower lipid levels by targeting hepatic production of proprotein convertase subtilisin\/kexin type 9. Unlike monoclonal antibodies, Inclisiran silences messenger RNA expression, resulting in sustained reductions in low-density lipoprotein cholesterol with infrequent dosing. This study aimed to systematically evaluate the efficacy and clinical applicability of Inclisiran across randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature search was conducted in PubMed, Scopus, Embase, and Cochrane CENTRAL databases up to December 2024. This meta-analysis updates the global evidence base by incorporating 14 randomized trials (&gt;\u200913,000 participants) identified through December 2024. Beyond earlier syntheses, it provides pooled analyses of multiple lipid parameters, phenotype-stratified subgroup and sensitivity analyses, and meta-regression for baseline LDL-C and statin use, thereby offering the most comprehensive and clinically differentiated evaluation of inclisiran to date. The primary outcome was the mean change in low-density lipoprotein cholesterol levels in patients treated with Inclisiran compared to placebo. Data was pooled using a random-effects model. Heterogeneity was assessed using the I\u00b2 statistic, and publication bias was evaluated with funnel plot analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Inclisiran treatment resulted in a significant mean reduction of 44.9% in low-density lipoprotein cholesterol levels compared to placebo (95% confidence interval: 39.54% to 50.25%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). While statistical heterogeneity was high (I\u00b2 = 90.3%), visual assessment of the funnel plot suggested minimal risk of publication bias. Subgroup analyses supported consistent efficacy across patient populations, including those with statin intolerance or poor adherence to conventional therapies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Inclisiran provides a durable, twice-yearly injectable option for lipid management, offering substantial reductions in low-density lipoprotein cholesterol. Its unique RNA-based mechanism and long-acting profile make it particularly suitable for patients who struggle with adherence or have limited response to traditional lipid-lowering medications. These findings support Inclisiran\u2019s role as a promising addition to current strategies for cardiovascular risk reduction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-026-05515-3","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T03:05:09Z","timestamp":1768014309000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management"],"prefix":"10.1186","volume":"26","author":[{"given":"Shakta Mani","family":"Satyam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"El-Tanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Anas","family":"Patni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Muhammad","family":"Irshad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Raheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esha","family":"Junais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashika Anu","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena Yusuf","family":"Rassal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sainath","family":"P","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"key":"5515_CR1","first-page":"8","volume":"1","author":"TA Gaziano","year":"2022","unstructured":"Gaziano TA. Cardiovascular diseases worldwide. Public Health Approach Cardiovasc Dis Prev Manag. 2022;1:8\u201318.","journal-title":"Public Health Approach Cardiovasc Dis Prev Manag"},{"issue":"1","key":"5515_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/ehjcvp\/pvad074","volume":"10","author":"WC Zheng","year":"2024","unstructured":"Zheng WC, Chan W, Dart A, Shaw JA. Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease. Eur Heart Journal-Cardiovascular Pharmacotherapy. 2024;10(1):53\u201367.","journal-title":"Eur Heart Journal-Cardiovascular Pharmacotherapy"},{"issue":"12","key":"5515_CR3","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","volume":"316","author":"MG Silverman","year":"2016","unstructured":"Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association between Lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289\u201397.","journal-title":"JAMA"},{"issue":"3","key":"5515_CR4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4103\/singaporemedj.SMJ-2024-172","volume":"66","author":"YH Mak","year":"2025","unstructured":"Mak YH, Chua F, Koh XH, Tan VH, Lee ZH, Lam A, et al. Low-density lipoprotein cholesterol goal attainment and mortality in ischaemic heart disease: a two-year observational study. Singapore Med J. 2025;66(3):154\u201362.","journal-title":"Singapore Med J"},{"key":"5515_CR5","doi-asserted-by":"publisher","unstructured":"Tall AR, Thomas DG, Gonzalez-Cabodevilla AG, Goldberg IJ. Addressing dyslipidemic risk beyond LDL-cholesterol. The Journal of clinical investigation. 2022;132(1). https:\/\/doi.org\/10.1172\/JCI148559.","DOI":"10.1172\/JCI148559"},{"issue":"12","key":"5515_CR6","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1001\/archinternmed.2010.182","volume":"170","author":"KK Ray","year":"2010","unstructured":"Ray KK, Seshasai SRK, Erqou S, Sever P, Jukema JW, Ford I, Sattar N. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65 229 participants. Arch Intern Med. 2010;170(12):1024\u201331.","journal-title":"Arch Intern Med"},{"issue":"9808","key":"5515_CR7","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/S0140-6736(11)61125-2","volume":"378","author":"HPSC Group","year":"2011","unstructured":"Group HPSC. Effects on 11-year mortality and morbidity of Lowering LDL cholesterol with Simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial. Lancet. 2011;378(9808):2013\u201320.","journal-title":"Lancet"},{"issue":"9","key":"5515_CR8","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.3390\/jcm12093187","volume":"12","author":"V Barrios","year":"2023","unstructured":"Barrios V, Pint\u00f3 X, Escobar C, Varona JF, G\u00e1mez JM. Real-world attainment of low-density lipoprotein cholesterol goals in patients at high risk of cardiovascular disease treated with high-intensity statins: the TERESA study. J Clin Med. 2023;12(9):3187.","journal-title":"J Clin Med"},{"issue":"7","key":"5515_CR9","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s11655-023-3545-z","volume":"30","author":"S-s Liu","year":"2024","unstructured":"Liu S-s, Yu T, Qiao Y-f, Gu S-x. Chai X-l. Research on hepatocyte regulation of PCSK9-LDLR and its related drug targets. Chin J Integr Med. 2024;30(7):664\u201372.","journal-title":"Chin J Integr Med"},{"issue":"1","key":"5515_CR10","first-page":"e201702","volume":"2017","author":"NG Seidah","year":"2017","unstructured":"Seidah NG. The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol. Global Cardiol Sci Pract. 2017;2017(1):e201702.","journal-title":"Global Cardiol Sci Pract"},{"issue":"1","key":"5515_CR11","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1146\/annurev-med-022613-090402","volume":"65","author":"EA Stein","year":"2014","unstructured":"Stein EA, Raal F. Reduction of low-density lipoprotein cholesterol by monoclonal antibody Inhibition of PCSK9. Annu Rev Med. 2014;65(1):417\u201331.","journal-title":"Annu Rev Med"},{"issue":"4","key":"5515_CR12","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1210\/clinem\/dgac708","volume":"108","author":"CB Newman","year":"2023","unstructured":"Newman CB, Tobert JA. Targeting PCSK9 with antibodies and gene Silencing to reduce LDL cholesterol. J Clin Endocrinol Metabolism. 2023;108(4):784\u201390.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"5","key":"5515_CR13","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","volume":"168","author":"GG Schwartz","year":"2014","unstructured":"Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014;168(5):682\u20139. e1.","journal-title":"Am Heart J"},{"issue":"1","key":"5515_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/14740338.2022.1988568","volume":"21","author":"Y Banerjee","year":"2022","unstructured":"Banerjee Y, Pantea Stoian A, Cicero AFG, Fogacci F, Nikolic D, Sachinidis A, et al. Inclisiran: A small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia. Exp Opin Drug Saf. 2022;21(1):9\u201320.","journal-title":"Exp Opin Drug Saf"},{"issue":"6","key":"5515_CR15","doi-asserted-by":"publisher","first-page":"e032031","DOI":"10.1161\/JAHA.123.032031","volume":"13","author":"MJ Wilkinson","year":"2024","unstructured":"Wilkinson MJ, Bajaj A, Brousseau ME, Taub PR. Harnessing RNA interference for cholesterol lowering: the bench-to\u2010bedside story of inclisiran. J Am Heart Association. 2024;13(6):e032031.","journal-title":"J Am Heart Association"},{"issue":"2","key":"5515_CR16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1039\/D4MD00652F","volume":"16","author":"F Ram\u00edrez-Cort\u00e9s","year":"2025","unstructured":"Ram\u00edrez-Cort\u00e9s F, M\u00e9nov\u00e1 P. Hepatocyte targeting via the Asialoglycoprotein receptor. RSC Med Chem. 2025;16(2):525\u201344.","journal-title":"RSC Med Chem"},{"key":"5515_CR17","doi-asserted-by":"crossref","unstructured":"Tosar JP. Small interfering RNAs (siRNAs). Biotherapeutics: from small to large molecules and cells. Springer; 2024. pp. 149\u201371.Calzada V, Cerecetto H, Tosar JP, editors. Biotherapeutics: From small to large molecules and cells. Springer Nature; 2025.","DOI":"10.1007\/7355_2024_171"},{"issue":"1","key":"5515_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41574-018-0110-5","volume":"15","author":"RM Stoekenbroek","year":"2019","unstructured":"Stoekenbroek RM, Lambert G, Cariou B, Hovingh GK. Inhibiting PCSK9\u2014biology beyond LDL control. Nat Reviews Endocrinol. 2019;15(1):52\u201362.","journal-title":"Nat Reviews Endocrinol"},{"key":"5515_CR19","doi-asserted-by":"publisher","first-page":"764038","DOI":"10.3389\/fcvm.2021.764038","volume":"8","author":"X-d Xia","year":"2021","unstructured":"Xia X-d, Peng Z-s, Gu H-m, Wang M, Wang G-q. Zhang D-w. Regulation of PCSK9 expression and function: mechanisms and therapeutic implications. Front Cardiovasc Med. 2021;8:764038.","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"5515_CR20","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3390\/pharmaceutics15020323","volume":"15","author":"\u0141 Wo\u0142owiec","year":"2023","unstructured":"Wo\u0142owiec \u0141, Osiak J, Wo\u0142owiec A, Wijata A, Grze\u015bk E, Kozakiewicz M, et al. Inclisiran\u2014safety and effectiveness of small interfering RNA in Inhibition of PCSK-9. Pharmaceutics. 2023;15(2):323.","journal-title":"Pharmaceutics"},{"key":"5515_CR21","doi-asserted-by":"publisher","unstructured":"Cesaro A, Acerbo V, Scialla F, Zito A, Porcelli G, Panico D, Argenziano G, Iaria D, Monaco MG, De Sio V, Gragnano F. Reduction of Visit-to-Visit LDL-C Intraindividual Variability in Patients Treated with PCSK9 Inhibitors and Inclisiran Versus Standard Lipid-Lowering Therapy. Journal of Clinical Lipidology. 2025. https:\/\/doi.org\/10.1016\/j.jacl.2025.10.066.","DOI":"10.1016\/j.jacl.2025.10.066"},{"issue":"2","key":"5515_CR22","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jacl.2022.01.001","volume":"16","author":"D Kallend","year":"2022","unstructured":"Kallend D, Stoekenbroek R, He Y, Smith PF, Wijngaard P. Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment. J Clin Lipidol. 2022;16(2):208\u201319.","journal-title":"J Clin Lipidol"},{"issue":"12","key":"5515_CR23","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1080\/17425255.2021.2029402","volume":"17","author":"B Tomlinson","year":"2021","unstructured":"Tomlinson B, Chow E, Chan P, Lam CWK. An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease. Expert Opin Drug Metab Toxicol. 2021;17(12):1353\u201361.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"5515_CR24","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jacl.2023.04.010","volume":"17","author":"Z Luo","year":"2023","unstructured":"Luo Z, Huang Z, Sun F, Guo F, Wang Y, Kao S, et al. The clinical effects of inclisiran, a first-in-class LDL-C Lowering SiRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia. J Clin Lipidol. 2023;17(3):392\u2013400.","journal-title":"J Clin Lipidol"},{"issue":"11","key":"5515_CR25","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1001\/jamacardio.2019.3502","volume":"4","author":"KK Ray","year":"2019","unstructured":"Ray KK, Stoekenbroek RM, Kallend D, Nishikido T, Leiter LA, Landmesser U, et al. Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial. JAMA Cardiol. 2019;4(11):1067\u201375.","journal-title":"JAMA Cardiol"},{"key":"5515_CR26","doi-asserted-by":"publisher","unstructured":"Albosta MS, Grant JK, Taub P, Blumenthal RS, Martin SS, Michos ED. Inclisiran: a new strategy for LDL-C lowering and prevention of atherosclerotic cardiovascular disease. Vascular health and risk management. 2023:421\u201331. https:\/\/doi.org\/10.2147\/VHRM.S338424.","DOI":"10.2147\/VHRM.S338424"},{"key":"5515_CR27","doi-asserted-by":"publisher","unstructured":"Koenig W, Ray KK, Kallend DG, Landmesser U, Leiter LA, Schwartz GG, Wright RS, Garcia Conde L, Jaros M, Raal FJ. Efficacy and safety of inclisiran in patients with established cerebrovascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised clinical trials. European Heart Journal. 2021 Oct 1;42(Supplement_1):ehab724\u20132026. https:\/\/doi.org\/10.1093\/eurheartj\/ehab724.2026.","DOI":"10.1093\/eurheartj\/ehab724.2026"},{"key":"5515_CR28","doi-asserted-by":"publisher","unstructured":"Wright RS, Ray KK, Landmesser U, Koenig W, Raal FJ, Leiter LA, Conde LG, Han J, Schwartz GG. Effects of inclisiran in patients with atherosclerotic cardiovascular disease: a pooled analysis of the ORION-10 and ORION-11 randomized trials. InMayo Clinic Proceedings 2024 Aug 1 (Vol. 99, No. 8, pp. 1222\u20131235). Elsevier. https:\/\/doi.org\/10.1016\/j.mayocp.2024.03.025.","DOI":"10.1016\/j.mayocp.2024.03.025"},{"key":"5515_CR29","doi-asserted-by":"publisher","unstructured":"L\u00f3pez-Miranda J. Efficacy, benefit and safety of inclisiran. Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis (English Edition). 2024;36:100730. https:\/\/doi.org\/10.1016\/j.artere.2025.100730.","DOI":"10.1016\/j.artere.2025.100730"},{"key":"5515_CR30","doi-asserted-by":"publisher","unstructured":"Li B, Chen Y, Zhang Y, Qian M, Shan Q, Qian J, Guo J. Adverse events associated with inclisiran: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS). Expert Opinion on Drug Safety. 2025:1\u20132. https:\/\/doi.org\/10.1080\/14740338.2025.2468855.","DOI":"10.1080\/14740338.2025.2468855"},{"issue":"6","key":"5515_CR31","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s40256-021-00477-7","volume":"21","author":"J Hardy","year":"2021","unstructured":"Hardy J, Niman S, Pereira E, Lewis T, Reid J, Choksi R, Goldfaden RF. A critical review of the efficacy and safety of inclisiran. Am J Cardiovasc Drugs. 2021;21(6):629\u201342.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"3","key":"5515_CR32","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s10557-021-07293-w","volume":"37","author":"S Bellosta","year":"2023","unstructured":"Bellosta S, Rossi C, Alieva A, Catapano A, Corsini A, Baragetti A. Cholesterol Lowering biotechnological strategies: from monoclonal antibodies to antisense therapies. A pre-clinical perspective review. Cardiovasc Drugs Ther. 2023;37(3):585\u201398.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"5515_CR33","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.clinthera.2023.12.003","volume":"46","author":"S Iqbal","year":"2024","unstructured":"Iqbal S, Sabbour HM, Ashraf T, Santos RD, Buckley A. First report of inclisiran utilization for hypercholesterolemia treatment in real-world clinical settings in a middle East population. Clin Ther. 2024;46(3):186\u201393.","journal-title":"Clin Ther"},{"issue":"8","key":"5515_CR34","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s40273-022-01152-8","volume":"40","author":"K Galactionova","year":"2022","unstructured":"Galactionova K, Salari P, Mattli R, Rachamin Y, Meier R, Schwenkglenks M. Cost-effectiveness, burden of disease and budget impact of inclisiran: dynamic cohort modelling of a real-world population with cardiovascular disease. PharmacoEconomics. 2022;40(8):791\u2013806.","journal-title":"PharmacoEconomics"},{"key":"5515_CR35","doi-asserted-by":"publisher","unstructured":"Landmesser U, Laufs U, Schatz U, Winzer EB, Nowak B, Kassner U, Gouni-Berthold I, Esteban A, Lubyayi L, Krueger A, Hentschke C. Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-difference trial. European Heart Journal. 2025:ehaf685. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf685.","DOI":"10.1093\/eurheartj\/ehaf685"},{"issue":"5","key":"5515_CR36","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3390\/antibiotics14050459","volume":"14","author":"SM Satyam","year":"2025","unstructured":"Satyam SM, El-Tanani M, Patni MA, Rehman A, Wali AF, Rangraze IR, et al. Repurposing anthelmintic drugs for COVID-19 treatment: A comprehensive meta-analysis of randomized clinical trials on Ivermectin and Mebendazole. Antibiotics. 2025;14(5):459.","journal-title":"Antibiotics"},{"key":"5515_CR37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jclinepi.2020.06.015","volume":"126","author":"S Minozzi","year":"2020","unstructured":"Minozzi S, Cinquini M, Gianola S, Gonzalez-Lorenzo M, Banzi R. The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application. J Clin Epidemiol. 2020;126:37\u201344.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"5515_CR38","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2337\/dc18-1491","volume":"42","author":"LA Leiter","year":"2019","unstructured":"Leiter LA, Teoh H, Kallend D, Wright RS, Landmesser U, Wijngaard PL, et al. Inclisiran lowers LDL-C and PCSK9 irrespective of diabetes status: the ORION-1 randomized clinical trial. Diabetes Care. 2019;42(1):173\u20136.","journal-title":"Diabetes Care"},{"issue":"16","key":"5515_CR39","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the treatment of heterozygous Familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520\u201330.","journal-title":"N Engl J Med"},{"issue":"8","key":"5515_CR40","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1111\/dom.15650","volume":"26","author":"LA Leiter","year":"2024","unstructured":"Leiter LA, Raal FJ, Schwartz GG, Koenig W, Ray KK, Landmesser U, et al. Inclisiran in individuals with diabetes or obesity: post hoc pooled analyses of the ORION-9, ORION\u201010 and ORION\u201011 phase 3 randomized trials. Diabetes Obes Metabolism. 2024;26(8):3223\u201337.","journal-title":"Diabetes Obes Metabolism"},{"issue":"6","key":"5515_CR41","doi-asserted-by":"publisher","first-page":"426","DOI":"10.7196\/SAMJ.2022.v112i6.16253","volume":"112","author":"F Raal","year":"2022","unstructured":"Raal F, Abelson M, Blignaut S, Burgess L, Coetzer S, Ebrahim I, et al. Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION phase III clinical trials. South Afr Med J. 2022;112(6):426\u201332.","journal-title":"South Afr Med J"},{"issue":"12","key":"5515_CR42","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1093\/cvr\/cvae109","volume":"120","author":"RS Wright","year":"2024","unstructured":"Wright RS, Raal FJ, Koenig W, Landmesser U, Leiter LA, Vikarunnessa S, et al. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovascular Res. 2024;120(12):1400\u201310.","journal-title":"Cardiovascular Res"},{"issue":"5","key":"5515_CR43","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.122.063460","volume":"149","author":"F Raal","year":"2024","unstructured":"Raal F, Durst R, Bi R, Talloczy Z, Maheux P, Lesogor A, et al. Efficacy, safety, and tolerability of inclisiran in patients with homozygous Familial hypercholesterolemia: results from the ORION-5 randomized clinical trial. Circulation. 2024;149(5):354\u201362.","journal-title":"Circulation"},{"issue":"16","key":"5515_CR44","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319.","journal-title":"N Engl J Med"},{"issue":"48","key":"5515_CR45","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1093\/eurheartj\/ehac615","volume":"43","author":"KK Ray","year":"2022","unstructured":"Ray KK, Kallend D, Leiter LA, Raal FJ, Koenig W, Jaros MJ, et al. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022;43(48):5047\u201357.","journal-title":"Eur Heart J"},{"issue":"6","key":"5515_CR46","doi-asserted-by":"publisher","first-page":"876","DOI":"10.5551\/jat.64454","volume":"31","author":"S Yamashita","year":"2024","unstructured":"Yamashita S, Kiyosue A, Maheux P, Mena-Madrazo J, Lesogor A, Shao Q, et al. Efficacy, safety, and pharmacokinetics of inclisiran in Japanese patients: results from ORION-15. J Atheroscler Thromb. 2024;31(6):876\u2013903.","journal-title":"J Atheroscler Thromb"},{"issue":"4","key":"5515_CR47","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1080\/14656566.2024.2337253","volume":"25","author":"F Barkas","year":"2024","unstructured":"Barkas F, Ray K. An update on inclisiran for the treatment of elevated LDL cholesterol. Expert Opin Pharmacother. 2024;25(4):349\u201358.","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"5515_CR48","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.3390\/jcm13051251","volume":"13","author":"F Agnello","year":"2024","unstructured":"Agnello F, Ingala S, Laterra G, Scalia L, Barbanti M. Novel and emerging LDL-C Lowering strategies: a new era of dyslipidemia management. J Clin Med. 2024;13(5):1251.","journal-title":"J Clin Med"},{"issue":"9","key":"5515_CR49","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1093\/eurjpc\/zwac025","volume":"29","author":"MD Reijman","year":"2022","unstructured":"Reijman MD, Schweizer A, Peterson AL, Bruckert E, Stratz C, Defesche JC, et al. Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous Familial hypercholesterolaemia. Eur J Prev Cardiol. 2022;29(9):1361\u20138.","journal-title":"Eur J Prev Cardiol"},{"issue":"13","key":"5515_CR50","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1161\/CIRCULATIONAHA.118.034710","volume":"138","author":"KK Ray","year":"2018","unstructured":"Ray KK, Stoekenbroek RM, Kallend D, Leiter LA, Landmesser U, Wright RS, et al. Effect of an SiRNA therapeutic targeting PCSK9 on atherogenic lipoproteins: prespecified secondary end points in ORION 1. Circulation. 2018;138(13):1304\u201316.","journal-title":"Circulation"},{"issue":"9753","key":"5515_CR51","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"CT Trialists","year":"2010","unstructured":"Trialists CT. Efficacy and safety of more intensive Lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381.","journal-title":"Lancet"},{"issue":"1","key":"5515_CR52","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/cvr\/cvaa077","volume":"117","author":"U Landmesser","year":"2021","unstructured":"Landmesser U, Haghikia A, Leiter LA, Wright RS, Kallend D, Wijngaard P, et al. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin\/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1. Cardiovascular Res. 2021;117(1):284\u201391.","journal-title":"Cardiovascular Res"},{"issue":"3","key":"5515_CR53","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1208\/s12248-024-00914-w","volume":"26","author":"KK Ballman","year":"2024","unstructured":"Ballman KK, Peek VL, Sloan JH, Li J, Konrad RJ, Wen Y. Cross-Reactive polyclonal antibodies Raised against GalNAc-Conjugated SiRNA recognize mostly the GalNAc moiety. AAPS J. 2024;26(3):41.","journal-title":"AAPS J"},{"issue":"2","key":"5515_CR54","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/antib7020019","volume":"7","author":"KP Pratt","year":"2018","unstructured":"Pratt KP. Anti-drug antibodies: emerging approaches to predict, reduce or reverse biotherapeutic immunogenicity. Antibodies. 2018;7(2):19.","journal-title":"Antibodies"},{"issue":"2","key":"5515_CR55","first-page":"e70039","volume":"8","author":"J Basit","year":"2025","unstructured":"Basit J, Ahmed M, Singh P, Ahsan A, Zulfiqar E, Iqbal J, Endocrinology, et al. Diabetes Metab. 2025;8(2):e70039.","journal-title":"Diabetes Metab"},{"issue":"5","key":"5515_CR56","doi-asserted-by":"publisher","first-page":"103779","DOI":"10.1016\/j.numecd.2024.10.017","volume":"35","author":"Z Cheng","year":"2025","unstructured":"Cheng Z, Gao M, Liu Y, Yan W, Zhang Z, Jiao N, Li C. Safety and efficacy of inclisiran in treating hypercholesterolemia: A systemic review and meta-analysis. Nutr Metabolism Cardiovasc Dis. 2025;35(5):103779.","journal-title":"Nutr Metabolism Cardiovasc Dis"},{"issue":"2","key":"5515_CR57","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/14740338.2023.2293201","volume":"23","author":"S Dutta","year":"2024","unstructured":"Dutta S, Shah R, Singhal S, Singh S, Piparva K, Katoch CDS. A systematic review and meta-analysis of tolerability, cardiac safety and efficacy of inclisiran for the therapy of hyperlipidemic patients. Exp Opin Drug Saf. 2024;23(2):187\u201398.","journal-title":"Exp Opin Drug Saf"},{"key":"5515_CR58","doi-asserted-by":"crossref","unstructured":"Khalil I, Rahman MT, Hossain I. The impact of inclisiran on lipid profiles in adults with hyperlipidemia: A meta-Analysis and meta regression of randomized controlled trials. The American Journal of Cardiology; 2025.","DOI":"10.1016\/j.amjcard.2025.04.013"},{"issue":"5","key":"5515_CR59","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1080\/00325481.2020.1751422","volume":"132","author":"C W\u00f3jcik","year":"2020","unstructured":"W\u00f3jcik C. Emerging lipid Lowering agents targeting LDL cholesterol. Postgrad Med. 2020;132(5):433\u201340.","journal-title":"Postgrad Med"},{"key":"5515_CR60","doi-asserted-by":"publisher","first-page":"215013192412363","DOI":"10.1177\/21501319241236339","volume":"15","author":"CN Deaney","year":"2024","unstructured":"Deaney CN, Donaldson MP, Reesby DM, Scott VL, Ellis V, Cole GE, et al. Retrospective evaluation of LDL-C levels following first treatment with inclisiran as part of secondary prevention ASCVD risk reduction in a real-world primary care setting. J Prim Care Community Health. 2024;15:21501319241236339.","journal-title":"J Prim Care Community Health"},{"issue":"2","key":"5515_CR61","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1080\/00325481.2015.998987","volume":"127","author":"MJ Koren","year":"2015","unstructured":"Koren MJ, Roth EM, McKenney JM, Gipe D, Hanotin C, Ferrand A-C, et al. Safety and efficacy of Alirocumab 150\u00a0mg every 2 weeks, a fully human proprotein convertase subtilisin\/kexin type 9 monoclonal antibody: A phase II pooled analysis. Postgrad Med. 2015;127(2):125\u201332.","journal-title":"Postgrad Med"},{"issue":"21","key":"5515_CR62","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1111\/bph.15972","volume":"180","author":"P Ranasinghe","year":"2023","unstructured":"Ranasinghe P, Addison ML, Dear JW, Webb DJ. Small interfering RNA: Discovery, Pharmacology and clinical development\u2014An introductory review. Br J Pharmacol. 2023;180(21):2697\u2013720.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"5515_CR63","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/17425247.2025.2466767","volume":"22","author":"Z-X Qin","year":"2025","unstructured":"Qin Z-X, Zuo L, Zeng Z, Ma R, Xie W, Zhu X, Zhou X. GalNac-siRNA conjugate delivery technology promotes the treatment of typical chronic liver diseases. Expert Opin Drug Deliv. 2025;22(4):455\u201369.","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"5515_CR64","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41392-023-01690-3","volume":"9","author":"X Bao","year":"2024","unstructured":"Bao X, Liang Y, Chang H, Cai T, Feng B, Gordon K, et al. Targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9): from bench to bedside. Signal Transduct Target Therapy. 2024;9(1):13.","journal-title":"Signal Transduct Target Therapy"},{"issue":"2","key":"5515_CR65","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3390\/biomedicines11020503","volume":"11","author":"AV Poznyak","year":"2023","unstructured":"Poznyak AV, Sukhorukov VN, Eremin II, Nadelyaeva II, Gutyrchik NA, Orekhov AN. Proprotein convertase subtilisin\/kexin 9 as a modifier of lipid metabolism in atherosclerosis. Biomedicines. 2023;11(2):503.","journal-title":"Biomedicines"},{"issue":"1","key":"5515_CR66","first-page":"8129513","volume":"2022","author":"I Mer\u0107ep","year":"2022","unstructured":"Mer\u0107ep I, Fri\u0161\u010di\u0107 N, Striki\u0107 D, Reiner \u017d. Advantages and disadvantages of inclisiran: a small interfering ribonucleic acid molecule targeting PCSK9\u2014a narrative review. Cardiovasc Ther. 2022;2022(1):8129513.","journal-title":"Cardiovasc Ther"},{"issue":"4","key":"5515_CR67","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/08916934.2022.2051142","volume":"55","author":"Z Wang","year":"2022","unstructured":"Wang Z, Chen X, Liu J, Wang Y, Zhang S. Inclisiran inhibits oxidized low-density lipoprotein-induced foam cell formation in Raw264. 7 macrophages via activating the PPAR\u03b3 pathway. Autoimmunity. 2022;55(4):223\u201332.","journal-title":"Autoimmunity"},{"issue":"4","key":"5515_CR68","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.3390\/ijms24044019","volume":"24","author":"O Ebenezer","year":"2023","unstructured":"Ebenezer O, Comoglio P, Wong GK-S, Tuszynski JA. Development of novel SiRNA therapeutics: a review with a focus on inclisiran for the treatment of hypercholesterolemia. Int J Mol Sci. 2023;24(4):4019.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"5515_CR69","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s11886-020-01427-6","volume":"22","author":"D Sinning","year":"2020","unstructured":"Sinning D, Landmesser U. Low-density lipoprotein-cholesterol Lowering strategies for prevention of atherosclerotic cardiovascular disease: focus on SiRNA treatment targeting PCSK9 (Inclisiran). Curr Cardiol Rep. 2020;22(12):176.","journal-title":"Curr Cardiol Rep"},{"issue":"2","key":"5515_CR70","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","volume":"11","author":"KK Ray","year":"2023","unstructured":"Ray KK, Troquay RP, Visseren FL, Leiter LA, Wright RS, Vikarunnessa S, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023;11(2):109\u201319.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"5515_CR71","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/cpt.2774","volume":"113","author":"NH Gosselin","year":"2023","unstructured":"Gosselin NH, Schuck VJ, Barriere O, Kulmatycki K, Margolskee A, Smith P, He Y. Translational population-pharmacodynamic modeling of a novel long\u2010acting SiRNA therapy, inclisiran, for the treatment of hypercholesterolemia. Clin Pharmacol Ther. 2023;113(2):328\u201338.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"5515_CR72","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40256-024-00712-x","volume":"25","author":"T Mansoor","year":"2025","unstructured":"Mansoor T, Rao BH, Gupta K, Parikh SS, Abramov D, Mehta A, et al. Inclisiran as a SiRNA inhibitor of proprotein convertase Subtilisin\/Kexin type 9 (PCSK9); Past, Present, and future. Am J Cardiovasc Drugs. 2025;25(3):293\u2013306.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"5","key":"5515_CR73","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11883-021-00918-3","volume":"23","author":"M Ruscica","year":"2021","unstructured":"Ruscica M, Ferri N, Santos RD, Sirtori CR, Corsini A. Lipid Lowering drugs: present status and future developments. Curr Atheroscler Rep. 2021;23(5):17.","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"5515_CR74","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/00045391-200401000-00011","volume":"11","author":"JM McKenney","year":"2004","unstructured":"McKenney JM. Optimizing LDL-C Lowering with Statins. Am J Ther. 2004;11(1):54\u20139.","journal-title":"Am J Ther"},{"issue":"12","key":"5515_CR75","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s40265-016-0613-0","volume":"76","author":"S Kr\u00e4henb\u00fchl","year":"2016","unstructured":"Kr\u00e4henb\u00fchl S, Pavik-Mezzour I, von Eckardstein A. Unmet needs in LDL-C lowering: when Statins won\u2019t do! Drugs. 2016;76(12):1175\u201390.","journal-title":"Drugs"},{"issue":"11","key":"5515_CR76","doi-asserted-by":"publisher","first-page":"e2025675","DOI":"10.1001\/jamanetworkopen.2020.25675","volume":"3","author":"M Banach","year":"2020","unstructured":"Banach M, Penson PE. Statins and LDL-C in secondary prevention\u2014So much progress, so Far to go. JAMA Netw Open. 2020;3(11):e2025675\u2013e.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"5515_CR77","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00392-016-1069-7","volume":"106","author":"H Soran","year":"2017","unstructured":"Soran H, Dent R, Durrington P. Evidence-based goals in LDL-C reduction. Clin Res Cardiol. 2017;106(4):237\u201348.","journal-title":"Clin Res Cardiol"},{"issue":"8","key":"5515_CR78","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/eurjcn\/zvae081","volume":"23","author":"GA Lee","year":"2024","unstructured":"Lee GA, Durante A, Baker EE, Vellone E, Caggianelli G, Dellafiore F, et al. Healthcare professionals\u2019 perspectives on the use of PCSK9 inhibitors in cardiovascular disease: an in-depth qualitative study. Eur J Cardiovasc Nurs. 2024;23(8):919\u201324.","journal-title":"Eur J Cardiovasc Nurs"},{"issue":"11","key":"5515_CR79","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jamacardio.2017.3451","volume":"2","author":"AM Navar","year":"2017","unstructured":"Navar AM, Taylor B, Mulder H, Fievitz E, Monda KL, Fievitz A, et al. Association of prior authorization and out-of-pocket costs with patient access to PCSK9 inhibitor therapy. JAMA Cardiol. 2017;2(11):1217\u201325.","journal-title":"JAMA Cardiol"},{"key":"5515_CR80","first-page":"100127","volume":"13","author":"AF Cicero","year":"2022","unstructured":"Cicero AF, Fogacci F, Zambon A, Toth PP, Borghi C. Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies. Am Heart J Plus: Cardiol Res Pract. 2022;13:100127.","journal-title":"Am Heart J Plus: Cardiol Res Pract"},{"issue":"6","key":"5515_CR81","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41573-022-00407-5","volume":"21","author":"A Goga","year":"2022","unstructured":"Goga A, Stoffel M. Therapeutic RNA-silencing oligonucleotides in metabolic diseases. Nat Rev Drug Discovery. 2022;21(6):417\u201339.","journal-title":"Nat Rev Drug Discovery"},{"issue":"6","key":"5515_CR82","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s11096-024-01784-0","volume":"46","author":"D Zou","year":"2024","unstructured":"Zou D, Hu Q, Liu Y, Yu L. Post-marketing pharmacovigilance study of inclisiran: mining and analyzing adverse event data from the FDA adverse event reporting system database. Int J Clin Pharm. 2024;46(6):1419\u201326.","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"5515_CR83","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jacl.2019.11.001","volume":"14","author":"K Dyrbu\u015b","year":"2020","unstructured":"Dyrbu\u015b K, G\u0105sior M, Penson P, Ray KK, Banach M. Inclisiran\u2014new hope in the management of lipid disorders? J Clin Lipidol. 2020;14(1):16\u201327.","journal-title":"J Clin Lipidol"},{"issue":"3","key":"5515_CR84","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jacc.2018.04.054","volume":"72","author":"RS Rosenson","year":"2018","unstructured":"Rosenson RS, Hegele RA, Fazio S, Cannon CP. The evolving future of PCSK9 inhibitors. J Am Coll Cardiol. 2018;72(3):314\u201329.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"5515_CR85","first-page":"101708","volume":"4","author":"J Cegla","year":"2025","unstructured":"Cegla J, Walji S, Barton L, Neuwirth C, Thompson GR. Treatment of homozygous Familial hypercholesterolemia. JACC: Adv. 2025;4(5):101708.","journal-title":"JACC: Adv"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-05515-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05515-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05515-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:32:09Z","timestamp":1781627529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-05515-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5515"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-05515-3","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,10]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"\u201cNot applicable\u201d. Ethical approval and consent to participate were not applicable for this systematic review and meta-analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"\u201cNot applicable\u201d.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"94"}}